Gianenrico Senna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9178919/publications.pdf

Version: 2024-02-01

53794 56724 8,185 188 45 83 citations h-index papers

g-index 190 190 190 6559 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. World Allergy Organization Journal, $2011, 4, 13-37$.	3.5	642
2	World Allergy Organization anaphylaxis guidelines: Summary. Journal of Allergy and Clinical Immunology, 2011, 127, 587-593.e22.	2.9	491
3	World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal, 2020, 13, 100472.	3.5	461
4	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal, 2014, 7, 6.	3 . 5	395
5	Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. Journal of Allergy and Clinical Immunology, 2009, 123, 680-686.	2.9	360
6	World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base. International Archives of Allergy and Immunology, 2013, 162, 193-204.	2.1	241
7	2012 Update. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 389-399.	2.3	236
8	Time to revisit the definition and clinical criteria for anaphylaxis?. World Allergy Organization Journal, 2019, 12, 100066.	3 . 5	137
9	Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy, 2012, 2, 21.	3.2	127
10	COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal, 2021, 14, 100517.	3.5	121
11	Causes of Food-Induced Anaphylaxis in Italian Adults: A Multi-Centre Study. International Archives of Allergy and Immunology, 2009, 150, 271-277.	2.1	118
12	The Severe Asthma Network in Italy: Findings and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1462-1468.	3.8	112
13	EpidemAAITO: Features of food allergy in Italian adults attending allergy clinics: a multiâ€centre study. Clinical and Experimental Allergy, 2009, 39, 547-555.	2.9	108
14	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine, the, 2021, 9, 260-274.	10.7	102
15	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	3.2	97
16	How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. Journal of Allergy and Clinical Immunology, 2010, 126, 668-669.	2.9	95
17	Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone, 2011, 49, 880-885.	2.9	95
18	Recommendations for assessing Patientâ€Reported Outcomes and Healthâ€Related quality of life in clinical trials on allergy: a GA ² LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 290-295.	5.7	92

#	Article	IF	CITATIONS
19	In chronic idiopathic urticaria autoantibodies against FceRII/CD23 induce histamine release via eosinophil activation. Clinical and Experimental Allergy, 2005, 35, 1599-1607.	2.9	87
20	Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. Journal of Allergy and Clinical Immunology, 2004, 113, 643-649.	2.9	85
21	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	3.5	82
22	How much specific is the association between hymenoptera venom allergy and mastocytosis?. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1379-1382.	5.7	79
23	Evidence of adherence to allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 544-548.	2.3	78
24	High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax, 2020, 75, 998-1000.	5 . 6	76
25	Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 840-844.	5.7	72
26	Minimal clinically important difference for asthma endpoints: an expert consensus report. European Respiratory Review, 2020, 29, 190137.	7.1	72
27	Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. Journal of Allergy and Clinical Immunology, 2008, 121, 256-257.	2.9	67
28	Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1091-1095.	5.7	64
29	Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Annals of Allergy, Asthma and Immunology, 2006, 97, 615-621.	1.0	62
30	Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA ² LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 959-968.	5.7	62
31	The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1029-1033.	5.7	62
32	Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: A double-blind study. Journal of Allergy and Clinical Immunology, 1996, 97, 34-41.	2.9	61
33	Health-related quality of life assessment in young adults with seasonal allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 313-317.	5.7	61
34	Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clinical and Experimental Allergy, 2013, 43, 22-28.	2.9	60
35	Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 561-564.	5.7	59
36	Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: Evaluation of A novel SLIT formulation during a Year). Pediatric Allergy and Immunology, 2007, 18, 58-62.	2.6	57

#	Article	IF	CITATIONS
37	One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101836.	2.6	57
38	Allergic rhinitis and asthma comorbidity: ARIA classification of rhinitis does not correlate with the prevalence of asthma. Clinical and Experimental Allergy, 2007, 37, 954-960.	2.9	56
39	Periostin: The bone and beyond. European Journal of Internal Medicine, 2017, 38, 12-16.	2.2	55
40	The natural history of respiratory allergy: A follow-up study of 99 patients up to 10 years. Respiratory Medicine, 2001, 95, 9-12.	2.9	54
41	Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). Journal of Allergy and Clinical Immunology, 2006, 117, 946-948.	2.9	51
42	Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1563-1569.	5.7	49
43	A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clinical and Experimental Allergy, 2009, 39, 1569-1574.	2.9	47
44	Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. Pulmonary Pharmacology and Therapeutics, 2015, 31, 123-129.	2.6	47
45	Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 849-854.	5.7	46
46	The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 65-68.	5.7	44
47	Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. Journal of the American Academy of Dermatology, 2003, 49, 714-716.	1.2	44
48	Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1193-1195.	5 . 7	44
49	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respiratory Medicine, 2021, 176, 106261.	2.9	44
50	Sex in Respiratory and Skin Allergies. Clinical Reviews in Allergy and Immunology, 2019, 56, 322-332.	6.5	42
51	Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19. Diagnostics, 2021, 11, 507.	2.6	41
52	Asthmatic patients in COVID-19 outbreak: Few cases despite many cases. Journal of Allergy and Clinical Immunology, 2020, 146, 541-542.	2.9	40
53	Cold-Induced Rhinitis in Skiers—Clinical Aspects and Treatment with Ipratropium Bromide Nasal Spray: A Randomized Controlled Trial. American Journal of Rhinology & Allergy, 2001, 15, 297-301.	2.2	38
54	Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulmonary Medicine, 2016, 16, 128.	2.0	38

#	Article	IF	CITATIONS
55	Therapeutic interventions in severe asthma. World Allergy Organization Journal, 2016, 9, 40.	3.5	38
56	AÂdouble-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. Clinical and Experimental Allergy, 2002, 32, 928-932.	2.9	37
57	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. Frontiers in Immunology, 2017, 8, 242.	4.8	37
58	Intimate behavior and allergy: a narrative review. Annals of Allergy, Asthma and Immunology, 2007, 99, 394-400.	1.0	36
59	Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Current Medical Research and Opinion, 2008, 24, 261-266.	1.9	36
60	SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. Clinical and Molecular Allergy, 2017, 15, 9.	1.8	36
61	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Realâ€ife observation. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2539-2541.	5.7	36
62	Standardization of Skin Tests for Diagnosis and Prevention of Hypersensitivity Reactions to Oxaliplatin. International Archives of Allergy and Immunology, 2008, 145, 54-57.	2.1	34
63	360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients. Clinical and Molecular Allergy, 2015, 13, 25.	1.8	34
64	A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1173-1180.	5 . 7	33
65	Correlation among FEV1, nitric oxide and asthma control test in newly diagnosed asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 207-8.	5.7	33
66	Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1064-1070.	5.7	33
67	COVIDâ€19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 871-874.	5.7	33
68	<scp>R</scp> hin <scp>A</scp> sthma Patient Perspective: a short daily asthma and rhinitisQo <scp>L</scp> assessment. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1443-1450.	5.7	31
69	Dropouts in sublingual allergen immunotherapy trials – a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 571-580.	5.7	31
70	Oral health in asthmatic patients: a review. Clinical and Molecular Allergy, 2020, 18, 22.	1.8	31
71	Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI. Allergy, Asthma and Immunology Research, 2021, 13, 219.	2.9	31
72	Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Review of Respiratory Medicine, 2022, 16, 713-721.	2.5	31

#	Article	IF	Citations
73	Shrimp Allergy in Italian Adults: A Multicenter Study Showing a High Prevalence of Sensitivity to Novel High Molecular Weight Allergens. International Archives of Allergy and Immunology, 2012, 157, 3-10.	2.1	30
74	Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 656-662.	2.3	30
75	Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clinical and Molecular Allergy, 2015, 13, 7.	1.8	30
76	Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. Pulmonary Pharmacology and Therapeutics, 2015, 31, 28-35.	2.6	30
77	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	3.5	30
78	Scombroid syndrome: it seems to be fish allergy but it isn't. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 516-521.	2.3	28
79	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respiratory Medicine, 2020, 171, 106080.	2.9	28
80	Are Physicians Aware of the Side Effects of Angiotensin-Converting Enzyme Inhibitors?. Chest, 2005, 128, 976-979.	0.8	27
81	Sensitization to Horse Allergens in Italy: A Multicentre Study in Urban Atopic Subjects without Occupational Exposure. International Archives of Allergy and Immunology, 2011, 155, 412-417.	2.1	27
82	COPD prevalence in a north-eastern Italian general population. Respiratory Medicine, 2015, 109, 1040-1047.	2.9	27
83	Fatal asthma; is it still an epidemic?. World Allergy Organization Journal, 2016, 9, 42.	3.5	27
84	Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies. Clinica Chimica Acta, 2016, 453, 170-173.	1.1	27
85	Are IgE Levels to Foods other than Rosaceae Predictive of Allergy in Lipid Transfer Protein-Hypersensitive Patients?. International Archives of Allergy and Immunology, 2011, 155, 149-154.	2.1	26
86	Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Expert Review of Respiratory Medicine, 2019, 13, 1205-1212.	2.5	25
87	Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clinical and Molecular Allergy, 2020, 18, 8.	1.8	25
88	Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services. Journal of Allergy and Clinical Immunology, 2003, 111, 1410-1412.	2.9	24
89	Uncontrolled Asthma: Unmet Needs in the Management of Patients. Journal of Asthma and Allergy, 2021, Volume 14, 457-466.	3.4	24
90	Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?. Current Treatment Options in Allergy, 2015, 2, 39-53.	2.2	23

#	Article	IF	CITATIONS
91	Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. Annals of Allergy, Asthma and Immunology, 2018, 120, 318-323.	1.0	21
92	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1386-1388.	3.8	21
93	COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. Vaccines, 2021, 9, 853.	4.4	21
94	Proposal of 0.5Âmg of protein/100Âg of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1736-1750.	5.7	21
95	Omalizumab management beyond clinical trials: The added value of a network model. Pulmonary Pharmacology and Therapeutics, 2014, 29, 74-79.	2.6	19
96	How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients. Internal and Emergency Medicine, 2015, 10, 937-941.	2.0	19
97	Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?. Vaccines, 2021, 9, 38.	4.4	19
98	Patients with Asthma and Comorbid Allergic Rhinitis: Is Optimal Quality of Life Achievable in Real Life?. PLoS ONE, 2012, 7, e31178.	2.5	19
99	Exercise-induced anaphylaxis to grape. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1235-1236.	5.7	18
100	The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy. International Archives of Allergy and Immunology, 2008, 147, 231-234.	2.1	18
101	Emerging drugs for allergic conjunctivitis. Expert Opinion on Emerging Drugs, 2014, 19, 291-302.	2.4	18
102	An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 375-380.	2.3	17
103	Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy. Clinical and Molecular Allergy, 2015, 13, 26.	1.8	17
104	Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Review of Clinical Immunology, 2015, 11, 233-245.	3.0	17
105	Study on the Immunoreactivity of <i>Triticum monococcum</i> (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods. Journal of Agricultural and Food Chemistry, 2015, 63, 8299-8306.	5.2	17
106	Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain. World Allergy Organization Journal, 2017, 10, 13.	3.5	17
107	The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. Clinical and Molecular Allergy, 2018, 16, 4.	1.8	17
108	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organization Journal, 2021, 14, 100592.	3.5	17

#	Article	IF	CITATIONS
109	Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. European Annals of Allergy and Clinical Immunology, 2006, 38, 31-4.	1.0	17
110	Allergy immunotherapy tablet: Grazax ^{\hat{A}^{\otimes}} for the treatment of grass pollen allergy. Expert Review of Clinical Immunology, 2011, 7, 21-27.	3.0	16
111	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1460-1463.	5.7	16
112	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. Clinical and Molecular Allergy, 2018, 16, 3.	1.8	15
113	Prevalence of latex-specific IgE in blood donors: an Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 80-81.	5.7	14
114	Food-Specific IgG4 Lack Diagnostic Value in Adult Patients with Chronic Urticaria and Other Suspected Allergy Skin Symptoms. International Archives of Allergy and Immunology, 2011, 155, 52-56.	2.1	14
115	The level of control of mild asthma in general practice: an observational community-based study. Journal of Asthma, 2014, 51, 91-96.	1.7	14
116	Potential benefit of omalizumab in respiratory diseases. Annals of Allergy, Asthma and Immunology, 2014, 113, 513-519.	1.0	14
117	Respiratory allergies in childhood: Recent advances andÂfuture challenges. Pediatric Allergy and Immunology, 2015, 26, 702-710.	2.6	14
118	Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world. Allergy, Asthma and Clinical Immunology, 2017, 13, 11.	2.0	14
119	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	3 . 5	14
120	ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respiratory Research, 2022, 23, 36.	3.6	14
121	Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors?. Journal of Allergy and Clinical Immunology, 2010, 125, 1171.	2.9	13
122	Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 208-218.	3.8	13
123	Arguing the misconceptions in allergen-specific immunotherapy. Immunotherapy, 2014, 6, 587-595.	2.0	12
124	Low adherence to inhaled corticosteroids/long-acting \hat{l}^2 ₂ -agonists and biologic treatment in severe asthmatics. ERJ Open Research, 2020, 6, 00017-2020.	2.6	12
125	A Survey of Clinical Features of Allergic Rhinitis in Adults. Medical Science Monitor, 2014, 20, 2151-2156.	1.1	12
126	Unconventional medicine: a risk of undertreatment of allergic patients. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1117-1119.	5.7	11

#	Article	IF	Citations
127	Pattern of use and diagnostic value of complementary/alternative tests for adverse reactions to food. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 1216-1217.	5.7	11
128	Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 966-967.	5.7	11
129	Anaphylaxis and intimate behaviour. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 350-355.	2.3	11
130	Uncontrolled severe asthma: starting from the unmet needs. Current Medical Research and Opinion, 2019, 35, 175-177.	1.9	11
131	Prevalence and features of asthma–chronic obstructive pulmonary disease overlap in Northern Italy general population. Journal of Asthma, 2019, 56, 27-33.	1.7	11
132	Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma. Rheumatology, 2021, 60, e59-e60.	1.9	11
133	Clinical efficacy and safety of local nasal immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 36-39.	5.7	10
134	Allergic rhinitis: pharmacotherapy in pregnancy and old age. Expert Review of Clinical Pharmacology, 2016, 9, 1081-1089.	3.1	10
135	Phenotyping asthma in the elderly: allergic sensitization profile and upper airways comorbidity in patients older than 65 years. Annals of Allergy, Asthma and Immunology, 2016, 116, 206-211.	1.0	10
136	The role of the pharmacy in the management of bronchial asthma. Annals of Allergy, Asthma and Immunology, 2017, 118, 161-165.	1.0	10
137	Anaphylaxis and Pregnancy: A Systematic Review and Call for Public Health Actions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4270-4278.	3.8	10
138	Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity?. Rhinology, 2014, 52, 66-71.	1.3	10
139	Severe Asthma, Telemedicine, and Self-Administered Therapy: Listening First to the Patient. Journal of Clinical Medicine, 2022, 11, 960.	2.4	10
140	Anaphylaxis due to carrot as hidden food allergen. Allergologia Et Immunopathologia, 2002, 30, 243-244.	1.7	9
141	Immunological Treatments for Occupational Allergy. International Journal of Immunopathology and Pharmacology, 2013, 26, 579-584.	2.1	9
142	Biologics for the Treatments of Allergic Conditions. Immunology and Allergy Clinics of North America, 2020, 40, 549-564.	1.9	9
143	Pizza, an unsuspected source of soybean allergen exposure. Allergy: European Journal of Allergy and Clinical Immunology, 1998, 53, 1106-1107.	5.7	8
144	Dermatological powder as hidden cause of occupational allergy due to casein: a case report. Occupational and Environmental Medicine, 2003, 60, 609-610.	2.8	8

#	Article	IF	CITATIONS
145	Is hymenoptera venom allergy an occupational disease?. Occupational and Environmental Medicine, 2008, 65, 217-218.	2.8	8
146	Allergy and the bone: unexpected relationships. Annals of Allergy, Asthma and Immunology, 2011, 107, 202-206.	1.0	8
147	Orphan immunotherapies for allergic diseases. Annals of Allergy, Asthma and Immunology, 2016, 116, 194-198.	1.0	8
148	Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients. Journal of Asthma, 2018, 55, 1028-1034.	1.7	8
149	Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy. World Allergy Organization Journal, 2019, 12, 100046.	3.5	8
150	<p>New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic</p> . Biologics: Targets and Therapy, 2019, Volume 13, 89-95.	3.2	8
151	Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry. Journal of Asthma and Allergy, 2020, Volume 13, 599-604.	3.4	8
152	Is alternative medicine acceptable in allergology?. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 1200-1200.	5.7	7
153	Local nasal immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 1995, 50, 190-190.	5.7	7
154	The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners. Clinical and Molecular Allergy, 2015, 13, 4.	1.8	7
155	Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings. Expert Opinion on Biological Therapy, 2019, 19, 919-925.	3.1	7
156	Molecular diagnosis and the Italian Board for ISAC. European Annals of Allergy and Clinical Immunology, 2014, 46, 68.	1.0	7
157	One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response. European Journal of Internal Medicine, 2022, 99, 112-115.	2.2	7
158	Likelihood ratios and Fagan's nomogram: valuable but underrated tools for in vitro latex sensitization assessment. Clinica Chimica Acta, 1999, 282, 175-183.	1.1	6
159	Specific immunotherapy among Italian specialists. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 898-899.	5.7	6
160	Type I variant of Kounis syndrome secondary to wasp sting. Annals of Allergy, Asthma and Immunology, 2012, 109, 79-81.	1.0	6
161	Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. Allergy and Asthma Proceedings, 2014, 35, 43-46.	2.2	6
162	Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol. Clinical and Translational Allergy, 2015, 5, 17.	3.2	6

#	Article	IF	Citations
163	Serum periostin during omalizumab therapy in asthma. Annals of Allergy, Asthma and Immunology, 2017, 119, 460-462.	1.0	6
164	Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 1036.	2.4	6
165	The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19. Clinical and Molecular Allergy, 2021, 19, 19.	1.8	6
166	What lies beyond Asthma Control Test: Suggestions for clinical practice. Journal of Asthma, 2016, 53, 559-562.	1.7	5
167	Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 273-275.	1.3	5
168	The Characteristics of Severe Chronic Upper-Airway Disease (SCUAD) in Patients with Allergic Rhinitis: A Real-Life Multicenter Cross-Sectional Italian Study. International Archives of Allergy and Immunology, 2019, 178, 333-337.	2.1	5
169	Effect of $\hat{l}\pm 1$ antitrypsin deficiency on lung volume decline in severe asthmatic patients undergoing biologic therapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1414-1416.	3.8	5
170	Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship?. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 411-417.	2.3	5
171	Evaluation of asthma control in the pharmacy: an Italian cross-sectional study. European Annals of Allergy and Clinical Immunology, 2017, 49, 225.	1.0	5
172	Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach?. Expert Review of Clinical Immunology, 2013, 9, 937-947.	3.0	4
173	Physicians' prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy. Clinical and Molecular Allergy, 2020, 18, 20.	1.8	4
174	Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. Journal of Asthma, 2022, 59, 1908-1913.	1.7	4
175	Asthma management among allergists in Italy: results from a survey. Clinical and Molecular Allergy, 2017, 15, 11.	1.8	3
176	The relevance of house dust mites allergy in clinical practice: the epidemiological impact on allergen immunotherapy. Immunotherapy, 2017, 9, 1219-1224.	2.0	3
177	Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. Annals of Medicine, 2022, 54, 869-874.	3.8	3
178	Latex-jujube cross-reactivity: case report and immunological study. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 971-972.	5.7	2
179	Update on the understanding, diagnosis and tailored management of anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 307-308.	2.3	2
180	The Relevance of Nasal Cytology in the Workup of House Dust Mite-Induced Allergic Rhinitis. Allergy, Asthma and Immunology Research, 2018, 10, 283.	2.9	2

#	Article	IF	CITATIONS
181	Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life. Immunotherapy, 2019, 11, 783-794.	2.0	2
182	Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 429-430.	2.3	2
183	Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?― Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2943-2944.	3.8	2
184	Nimesulide reduces skin-test reactivity. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 596-596.	5.7	1
185	Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 285-286.	1.3	1
186	Biologics for Eosinophilic Granulomatosis With Polyangiitisâ€"One Size Does Not Fit All: Comment on the Article by Canzian et al. Arthritis and Rheumatology, 2021, 73, 1346-1347.	5.6	1
187	Improving quality of life as an optimal goal of allergen immunotherapy. Clinical and Experimental Allergy Reviews, 2006, 6, 61-61.	0.3	О
188	Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply. Rheumatology, 2021, 60, e79-e80.	1.9	0